Structure via PubChem · Public domain (PubChem)
abrocitinib
Sign in to saveAlso known as PF-04965842, PF 04965842, PF04965842
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
Key facts
- Drug.image
- Abrocitinib.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Cibinqo
- Drug.MedlinePlus
- a622008
- Drug.DailyMedID
- Abrocitinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Janus kinase inhibitor
- Drug.ATC_prefix
- D11
- Drug.ATC_suffix
- AH08
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.elimination_half life
- 2.8–5.2 h
- Drug.excretion
- 1.0–4.4% unchanged in urine
- Drug.CAS_number
- 1622902-68-4
- Drug.PubChem
- 78323835
via Wikipedia infobox
Chemical data
- Formula
- C14H21N5O2S
- Molecular weight
- 323.42 g/mol
- IUPAC name
- N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2021
- Admin. routes
- oral
- Indications
- atopic eczema, psoriasis, liver disease, kidney disease
via ChEMBL · EBI
Research
555 papers- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.The New England journal of medicine · 2021
- Abrocitinib.2006
- Abrocitinib.2012
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.Health technology assessment (Winchester, England) · 2024
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2020
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 323.14159591199996
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₄H₂₁N₅O₂S
- canonical SMILES
- CCCS(=O)(=O)NC1CC(C1)N(C)c2c3cc[nH]c3ncn2
- medical condition treated
- atopic dermatitis
- legal status (medicine)
- boxed warning
- subject has role
- protein kinase inhibitors
- Commons category
- Abrocitinib
Sources (2)
via Wikidata · CC0
~10 min read
Encyclopedic overview
15 sectionsContents
- Medical uses
- Efficacy of abrocitinib in treating atopic dermatitis
- Side effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Other therapeutic effects of abrocitinib
- In pediatric peanut allergy
- Therapy of oral lichen planus
- Improving the lesions of extensive necrobiosis lipoidica
- References
- External links
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
The most common side effects include nausea (feeling sick), headache, acne, herpes simplex (viral infection of the mouth or the genitals), increased levels of creatine phosphokinase in the blood (an enzyme released into the blood when muscle is damaged), vomiting, dizziness and pain in the upper belly.
Excerpted from Wikipedia’s “abrocitinib” article, available under the CC BY-SA 4.0 licence.